Global Gene Therapy Market Report 2021: Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
Wednesday, July 21, 2021
DUBLIN, July 13, 2021 /PRNewswire/ -- The "Gene Therapy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Global market for Gene Therapy estimated at US$970.5 Million in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 19.5% over the period 2020-2027.
Viral, one of the segments analyzed in the report, is projected to grow at a 19.7% CAGR to reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Viral segment is readjusted to a revised 17.6% CAGR for the next 7-year period. This segment currently accounts for a 11.1% share of the global Gene Therapy market.
The U.S. Accounts for Over 53.7% of Global Market Size in 2020, While China is Forecast to Grow at a 25.1% CAGR for the Period of 2020-2027
The Gene Therapy market in the U.S. is estimated at US$521.3 Million in the year 2020. The country currently accounts for a 53.71% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$107.9 Million in the year 2027 trailing a CAGR of 25.1% through 2027.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.3% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 18.6% CAGR while Rest of European market (as defined in the study) will reach US$107.9 Million by the year 2027.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
-- Influencer Market Insights
-- World Market Trajectories
-- Impact of Covid-19 and a Looming Global Recession
-- A Prelude to Gene Therapy
-- Classification of Gene Therapies
-- COVID-19 Causes Gene Therapy Market to Buckle & Collapse
-- COVID-19 Impact on Different Aspects of Gene Therapy
-- Manufacturing & Delivery
-- Research & Clinical Development
-- Commercial Operations & Access
-- Managing Derailed Operations
-- Focus on Clinical Development Programs
-- Targeting Manufacturing & Delivery Strategies
-- Securing Supplies
-- Remote Working
-- Gene Therapy Set to Witness Rapid Growth Post COVID-19
-- By Vector Type
-- Viral Vectors Account For A Major Share Of The Market
-- Adeno-Associated Virus Vectors
-- Lentivirus
-- Non-Viral Vectors To Witness Faster Growth
-- US and Europe Dominate the Gene Therapy Market
-- Oncology Represents the Largest Indication for Gene Therapy
-- Market Outlook
-- WORLD BRANDS
2. FOCUS ON SELECT PLAYERS
-- Recent Market Activity
-- Select Innovations
-- Abeona Therapeutics Inc.
-- Adaptimmune Therapeutics Plc
-- Advantagene, Inc.
-- Adverum Biotechnologies, Inc
-- Akcea Therapeutics
-- Alnylam Pharmaceuticals, Inc.
-- Amgen Inc
-- Anchiano Therapeutics, Inc.
-- AnGes, Inc.
-- Applied Genetic Technologies Corporation
-- Audentes Therapeutics, Inc.
-- Biogen
-- bluebird bio, Inc.
-- Chiesi Farmaceutici S.p.A
-- CRISPR Therapeutics AG
-- Editas Medicine, Inc.
-- Gilead Sciences, Inc.
-- Intellia Therapeutics, Inc.
-- Jazz Pharmaceuticals, plc.
-- Juno Therapeutics, Inc
-- Merck KGaA
-- MolMed S.p.A.
-- Novartis Gene Therapies
-- Orchard Therapeutics plc
-- REGENXBIO Inc.
-- Sangamo Therapeutics, Inc.
-- Sarepta Therapeutics, Inc.
-- Sibiono GeneTech Co. Ltd.
-- Spark Therapeutics, Inc.
-- uniQure N.V.
-- Voyager Therapeutics
3. MARKET TRENDS & DRIVERS
-- Availability of Novel Therapies Drive Market Growth
-- Select Approved Gene Therapy Products
-- Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
-- Lentiviral Vectors Witness Increasing Interest
-- Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy
-- Compelling Level of Technology & Innovation to Ignite Gene Therapy
-- Promising Gene Therapy Innovations for Treatment of Inherited Retinal
Diseases
-- Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine
-- M&As Rampant in Gene Therapy Space
-- Gene Therapy Deals: 2018 and 2019
-- Emphasis on Formulating Robust Regulatory Framework
-- Strong Gene Therapy Pipeline
-- Gene Therapy: Phase III Clinical Trials
-- OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR
-- Growing Funding for Gene Therapy Research
-- Market Issues & Challenges
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
IV. COMPETITION
-- Total Companies Profiled: 154
For more information about this report visit https://www.researchandmarkets.com/r/4dxddh
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-gene-therapy-market-report-2021-adeno-associated-virus-vectors---a-leading-platform-for-gene-therapy-301332333.html
SOURCE Research and Markets
|
|
|
|
|
 |
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
|
